UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2022
Commission file number: 001-39838
Gracell Biotechnologies Inc.
Building 12, Block B, Phase II
Biobay Industrial Park
218 Sangtian St.
Suzhou Industrial Park, 215123
People’s Republic of China
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
RESOLUTIONS ADOPTED IN 2022 ANNUAL GENERAL MEETING
At Gracell Biotechnologies Inc.’s (the “Company”) annual general meeting of shareholders (“AGM”) held on September 15, 2022, all of the proposed resolutions put to the AGM were passed by the Company’s shareholders. Below are the resolutions passed:
| • | as an ordinary resolution, that Dr. Guotong Xu be re-elected as a Class II director of the Company at this annual general meeting, to serve for a full term of three (3) years, and |
| • | as an ordinary resolution, that Dr. David Guowei Wang be re-elected as a Class II director of the Company at this annual general meeting, to serve for a full term of three (3) years. |
INCORPORATION BY REFERENCE
This report on Form 6-K is hereby incorporated by reference in the registration statements of Gracell on Form F-3 (No. 333-264545) to the extent not superseded by documents or reports subsequently filed.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Gracell Biotechnologies Inc. | ||
| By: | /s/ William Wei Cao | |
| Name: | William Wei Cao | |
| Title: | Chairman of the Board of Directors and Chief Executive Officer | |
Date: September 15, 2022